FWY003 Clinical Trials (2026): 1 Studies for Geographic Atrophy Secondary to Age-related Macular Degeneration
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 FWY003 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Geographic Atrophy Secondary to Age-related Macular Degeneration) and 272 total planned enrollment. 1 FWY003 clinical trial is actively recruiting at 12 U.S. sites across 6 states. Most recent activity: NCT07441642 (Aug 2029).
Where to Participate: All FWY003 Trial Sites in the U.S. (12 sites across 6 states)
Every actively recruiting FWY003trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Salehi Retina Institute | Huntington Beach92647 | NCT07441642 | Map |
| CA | Retinal Consultants Medical Group Inc | Sacramento95841 | NCT07441642 | Map |
| CA | California Retina Consultants | Santa Barbara93103 | NCT07441642 | Map |
| FL | Advanced Research LLC | Boynton Beach33437 | NCT07441642 | Map |
| FL | Advanced Research LLC | Deerfield Beach33064 | NCT07441642 | Map |
| FL | Retina Vitreous Associates of Florida | St. Petersburg33711 | NCT07441642 | Map |
| MA | Opthamalic Consultants of Boston | Boston02114 | NCT07441642 | Map |
| NJ | NJ Retina | Toms River08755 | NCT07441642 | Map |
| PA | Erie Retina Research LLC | Erie16505 | NCT07441642 | Map |
| TX | Retina Consultants TX Rsrch Ctr | Bellaire77401 | NCT07441642 | Map |
| TX | Retina Consultants of Houston PA | Houston77030 | NCT07441642 | Map |
| TX | Retina Consultants of Texas | Katy77494 | NCT07441642 | Map |
FWY003 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P2 | 1 | 1 |
Recruiting FWY003 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07441642 | A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration | P2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | 272 | Mar 2026 |
All FWY003 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07441642 | A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration | P2 | recruiting | 272 | Novartis Pharmaceuticals | Mar 2026 |
FWY003 clinical trials: frequently asked questions
- How many FWY003 clinical trials are there?
- 1 FWY003 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are FWY003 clinical trials recruiting in 2026?
- Yes — 1 FWY003 trial is actively recruiting in 2026, with 12 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is FWY003 being studied for?
- FWY003 is being studied for Geographic Atrophy Secondary to Age-related Macular Degeneration. The trials are grouped by indication on this page.
- What phase is FWY003 in?
- FWY003 clinical trials span 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors FWY003 clinical trials?
- The lead sponsor across the most FWY003 trials is Novartis Pharmaceuticals. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming FWY003as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: